Who
Ross Moat
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Kiniksa Pharmaceuticals International.
In numbers
- Trades disclosed
- 177
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $6.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 15 Jul 2021
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,477 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —1,611 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,477 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —1,611 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —1,740 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —9,250 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —36,950 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,457 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —1,740 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —1,611 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,477 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,457 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code F | $318K4,007 at $79.28 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —9,250 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —36,950 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,457 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —1,740 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,477 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —1,611 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —1,740 | filing |
News
Head to Head Review: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Zenas BioPharma (NASDAQ:ZBIO)KNSA · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Ross Moat; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.